{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Medtronic Plc
Medtronic Plc Experiences Revision in Its Stock Evaluation Amid Strong Financial Performance
Medtronic Plc has reported strong financial results for the quarter ending July 2025, showcasing an operating cash flow of USD 7,146 million and a return on capital employed of 9.72%. The company also achieved a dividend per share of USD 5.57 and a high inventory turnover ratio of 2.43 times, despite facing challenges with a high debt-equity ratio of 42.78%.
Medtronic Hits New 52-Week High of $102.59, Showcasing Strong Growth
Medtronic Plc achieved a new 52-week high of USD 102.59 on November 19, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a 20.69% increase over the past year, with a market capitalization of USD 119,277 million and a dividend yield of 3.08%.
Medtronic Stock Hits Day High with Strong 4.69% Intraday Surge
Medtronic Plc's stock saw significant gains on November 18, 2025, reaching an intraday high. The company has outperformed the S&P 500 over the past week and month, with strong year-to-date returns. Key financial metrics highlight a solid operational foundation and stable investment environment, despite recent underperformance.
Medtronic Plc Experiences Revision in Stock Evaluation Amid Mixed Market Signals
Medtronic Plc, a key player in the Pharmaceuticals & Biotechnology sector, has seen its stock price slightly decrease to $94.13. Over the past year, it reached a high of $99.37 and a low of $79.29. The company's performance has varied, with a 3.45% annual return, but it outperformed the S&P 500 year-to-date.
Is Medtronic Plc technically bullish or bearish?
As of October 24, 2025, Medtronic Plc's technical trend is mildly bullish, supported by positive MACD and moving averages, but recent performance shows underperformance against the S&P 500, suggesting caution despite year-to-date outperformance.
Is Medtronic Plc technically bullish or bearish?
As of October 24, 2025, Medtronic Plc's technical trend is mildly bullish, supported by bullish MACD and Bollinger Bands, despite underperforming the S&P 500 recently while outperforming it year-to-date.
Is Medtronic Plc technically bullish or bearish?
As of October 24, 2025, Medtronic Plc's technical trend is mildly bullish, supported by positive MACD and KST indicators, but it has underperformed the S&P 500 recently, with mixed signals suggesting caution.
Medtronic Plc Hits New 52-Week High at USD 99.37
Medtronic Plc achieved a new 52-week high of USD 99.37 on October 7, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has gained 18.27% over the past year, with a market capitalization of USD 119,277 million and a dividend yield of 3.08%.
Medtronic Hits New 52-Week High of $98.65, Showcasing Strong Growth
Medtronic Plc achieved a new 52-week high of USD 98.65 on October 6, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has gained 18.39% over the past year, with a solid financial profile characterized by a favorable debt-to-equity ratio and attractive dividend yield.
Medtronic Hits New 52-Week High at $97.94, Showcasing Strong Growth
Medtronic Plc reached a new 52-week high of USD 97.94 on October 3, 2025, reflecting strong performance over the past year. With a market capitalization of USD 119,277 million, a P/E ratio of 21.00, and a dividend yield of 3.08%, the company demonstrates solid financial health and competitive valuation.
Is Medtronic Plc technically bullish or bearish?
As of September 4, 2025, Medtronic Plc's technical trend is bullish with strong indicators, outperforming the S&P 500 in the short term but underperforming over the longer three- and five-year periods.
Is Medtronic Plc overvalued or undervalued?
As of August 19, 2025, Medtronic Plc is fairly valued with a P/E ratio of 21, an EV to EBITDA of 15.42, and a PEG ratio of 1.00, showing competitive positioning against peers, while achieving a YTD return of 19.67%, outperforming the S&P 500's 12.22%, but underperforming over five years with a return of -11.16% compared to the S&P 500's 96.61%.
Is Medtronic Plc overvalued or undervalued?
As of June 16, 2025, Medtronic Plc is considered very attractive and undervalued, with favorable financial metrics including a P/E ratio of 21, an EV to EBITDA of 15.42, and a PEG ratio of 1.00, suggesting it offers better value compared to peers like Abbott Laboratories and Intuitive Surgical.
Is Medtronic Plc technically bullish or bearish?
As of June 17, 2025, the market trend is neutral with mixed indicators, showing mildly bullish signals on the weekly and monthly MACD, but bearish trends in daily moving averages and weekly KST, leading to an overall mildly bearish stance according to Dow Theory.
Who are in the management team of Medtronic Plc?
As of March 2022, Medtronic Plc's management team is led by Mr. Geoffrey Martha, who is the Executive Chairman, President, and CEO. The Board of Directors includes independent members such as Mr. Richard Anderson, Mr. Craig Arnold, Mr. Scott Donnelly, Ms. Andrea Goldsmith, and Mr. Randall Hogan.
What does Medtronic Plc do?
Medtronic Plc is a large-cap medical technology and services company with recent net sales of $8.93 billion and a net profit of $1.06 billion. Key metrics include a P/E ratio of 21.00 and a dividend yield of 3.34%.
How big is Medtronic Plc?
As of Jun 18, Medtronic Plc has a market capitalization of $110.52 billion, with net sales of $33.54 billion and a net profit of $4.69 billion over the latest four quarters. The company reported shareholder's funds of $48.02 billion and total assets of $91.68 billion as of Apr 25.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
